

SUPPLEMENTAL TABLES

eTable 1. Association between the market entry of biosimilar filgrastim and patient out-of-pocket costs for branded filgrastim products

	Change in Average Patient Out-of-Pocket Cost for 480 mcg of Branded Filgrastim (in U.S. Dollars ^a)	
	Level Change ^b	Slope Change ^c
Total Patient Out-of-Pocket Costs, Estimate, (95% CI)	-0.20 (-5.29: 4.90)	-0.08 (-0.41: 0.24)
By Type of Cost Estimate, (95% CI)		
Coinsurance	-1.50 (-3.29: 0.28)	0.06 (-0.08: 0.19)
Copayment	3.72 (-0.24: 7.68)	0.16 (-0.11: 0.38)
Deductible	-0.77 (-3.78: 2.24)	-0.13 (-0.35: 0.08)

^a Costs adjusted for inflation using the Medical Care Consumer Price Index and all amounts are presented in January 2014 U.S. Dollars

^b Level change represents the average change in costs following the intervention point (February 2016)

^c Slope change represents the average monthly change in cost trend over the post-intervention period relative to the baseline trend

*p <0.05

eTable 2. Sensitivity Analysis: Association between the market entry of biosimilar filgrastim, claims payments and patient out-of-pocket costs ^a

	Change in Average Amounts for 480 mcg of Branded Filgrastim (in U.S. Dollars ^b)	
	Level Change ^c	Slope Change ^d
All Branded Filgrastim products, Estimate, (95% CI)	-33.41 (-58.97: -7.85) *	-2.99 (-4.43: -1.54) *
Patient Out-of-Pocket Costs. Estimate, (95% CI)	-3.97 (-20.12: 12.17)	-0.02 (-0.83: 0.78)

^a In this sensitivity analysis, the “pre-intervention” trend was based on data from January 2014 to March 2015 (filgrastim-sndz approval date) only.

^b Amounts adjusted for inflation using the Medical Care Consumer Price Index and all amounts are presented in January 2014 U.S. Dollars

^c Level change represents the average change in claims payments or patient out-of-pocket costs following the intervention point (February 2016)

^d Slope change represents the average monthly change in cost trend over the post-intervention period relative to the baseline trend

*p<0.01

eTable 3. Sensitivity Analysis: Association between the market entry of biosimilar filgrastim, claims payments and patient out-of-pocket costs for referent filgrastim^a

	Change in Average Amounts for 480 mcg of Branded Filgrastim (in U.S. Dollars ^b)	
	Level Change ^c	Slope Change ^d
Referent filgrastim claims payments, Estimate, (95% CI)	-29.62 (-38.85: -20.39) *	-3.14 (-3.80: -2.48) *
Patient Out-of-Pocket Costs. Estimate, (95% CI)	-0.37 (-5.75: 5.01)	-0.23 (-0.57: 0.10)

^a In this sensitivity analysis, the analytical sample was restricted to referent filgrastim claims only.

^b Amounts adjusted for inflation using the Medical Care Consumer Price Index and all amounts are presented in January 2014 U.S. Dollars

^c Level change represents the average change in claims payments or patient out-of-pocket costs following the intervention point (February 2016)

^d Slope change represents the average monthly change in cost trend over the post-intervention period relative to the baseline trend

*p<0.01

eTable 4. Sensitivity Analysis: Association between the market entry of biosimilar filgrastim, claims payments and patient out-of-pocket costs ^a

	Change in Average Amounts for 480 mcg of Branded Filgrastim (in U.S. Dollars ^b)	
	Level Change ^c	Slope Change ^d
Referent filgrastim claims payments, Estimate, (95% CI)	-28.46 (-38.10: -18.81) *	-3.18 (-3.96: -2.40) *
Patient Out-of-Pocket Costs. Estimate, (95% CI)	-1.58 (-5.78: 2.61)	0.06 (-0.21: 0.33)

^a In this sensitivity analysis, the analytical sample was restricted to claims for 300 mcg, 480 mcg or a combination of both.

^b Amounts adjusted for inflation using the Medical Care Consumer Price Index and all amounts are presented in January 2014 U.S. Dollars

^c Level change represents the average change in claims payments or patient out-of-pocket costs following the intervention point (February 2016)

^d Slope change represents the average monthly change in cost trend over the post-intervention period relative to the baseline trend

*p<0.01